SI9300114B - 5-ht4-receptor antagonists - Google Patents

5-ht4-receptor antagonists Download PDF

Info

Publication number
SI9300114B
SI9300114B SI9300114A SI9300114A SI9300114B SI 9300114 B SI9300114 B SI 9300114B SI 9300114 A SI9300114 A SI 9300114A SI 9300114 A SI9300114 A SI 9300114A SI 9300114 B SI9300114 B SI 9300114B
Authority
SI
Slovenia
Prior art keywords
pharmaceutically acceptable
oxazino
piperidyl
carboxamide
dihydro
Prior art date
Application number
SI9300114A
Other languages
Slovenian (sl)
Other versions
SI9300114A (en
Inventor
Laramie Mary Gaster
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929205428A external-priority patent/GB9205428D0/en
Priority claimed from GB929218846A external-priority patent/GB9218846D0/en
Priority claimed from GB929227045A external-priority patent/GB9227045D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SI9300114A publication Critical patent/SI9300114A/en
Publication of SI9300114B publication Critical patent/SI9300114B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds with the formula (I) and their pharmaceutically acceptable salts, their use in pharmaceuticals for the treatment of gastrointestinal, cardiovascular and CNS disorders are described. (I)

Claims (8)

1 PATENTNI ZAHTEVKI 1. N-(l-nButil-4-piperidil)metil-3,4-dihidro-2H-[l,3]oksazino[3,2-a]indol-10-karboksamid ali njegova farmacevtsko sprejemljiva sol.1 PATENT CLAIMS 1. N- (1-N-Butyl-4-piperidyl) methyl-3,4-dihydro-2H- [1,3] oxazino [3,2-a] indole-10-carboxamide or a pharmaceutically acceptable salt thereof. 2. N-(l-nButil-4-piperidil)metil-3,4-dihidro-2H-[l,3]oksazino[3,2-a]indol-10-karboksamid.2. N- (1-n-Butyl-4-piperidyl) methyl-3,4-dihydro-2H- [1,3] oxazino [3,2-a] indole-10-carboxamide. 3. Farmacevtsko sprejemljiva sol po zahtevku 1, ki je kislinska adicijska sol s klorovodikovo, bromovodikovo, borovo, fosforjevo ali žveplovo kislino ali s farmacevtsko sprejemljivo organsko kislino.A pharmaceutically acceptable salt of claim 1 which is an acid addition salt with hydrochloride, hydrobromic, boric, phosphoric or sulfuric acid or with a pharmaceutically acceptable organic acid. 4. Farmacevtsko sprejemljiva sol po zahtevku 1, ki je kislinska adicijska sol s klorovodikovo, bromovodikovo, borovo, fosforjevo, žveplovo, ocetno, vinsko, maleinsko, citronsko, jantarno, benzojsko, askorbinsko, metansulfonsko, a-keto glutarjevo, α-glicerofosforjevo ali glukoza-1-fosforjevo kislino.The pharmaceutically acceptable salt of claim 1 which is an acid addition salt with hydrochloric, hydrobromic, pine, phosphorus, sulfur, acetic, tartaric, maleic, citric, succinic, benzoic, ascorbic, methanesulfonic, a-keto glutar, α-glycerophosphoric or glucose-1-phosphoric acid. 5. Hidrokloridna sol N-(l-nbutil-4-piperidil)metil-3,4-dihidro-2H-[l,3]oksazino[3,2-ajindol-10-karboksamida.The hydrochloride salt of N- (1-n-butyl-4-piperidyl) methyl-3,4-dihydro-2H- [1,3] oxazino [3,2-ayindole-10-carboxamide. 6. Farmacevtski sestavek, ki obsega N-(l-nbutil-4-piperidil)metil-3,4-dihidro-2H-[l,3]oksazino[3,2-a]indol-10-karboksamid ali njegovo farmacevtsko sprejemljivo sol po kateremkoli od zahtevkov 1 do 5 in farmacevtsko sprejemljiv nosilec.A pharmaceutical composition comprising N- (1-n-butyl-4-piperidyl) methyl-3,4-dihydro-2H- [1,3] oxazino [3,2-a] indole-10-carboxamide or a pharmaceutically acceptable salt according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier. 7. N-( 1 -nButil-4-piperidil)metil-3,4-dihidro-2H-[ 1,3]oksazino[3,2-a]indol-10-karboksamid ali njegova farmacevtsko sprejemljiva sol po kateremkoli od zahtevkov 1 do 5 za uporabo kot učinkovita terapevtska substanca.N- (1-Butyl-4-piperidyl) methyl-3,4-dihydro-2H- [1,3] oxazino [3,2-a] indole-10-carboxamide or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 for use as an effective therapeutic substance. 8. Uporaba N-( 1 -nbutil-4-piperidil)metil-3,4-dihidro-2H- [ 1,3]oksazino[3,2-a]indol-10-karboksamida za pripravo zdravila za uporabo kot antagonista 5-HT4 receptorja pri 2 zdravljenju ali profilaksi gastrointestinalnih motenj, kardiovaskularnih motenj in CNS motenj.Use of N- (1-butyl-4-piperidyl) methyl-3,4-dihydro-2H- [1,3] oxazino [3,2-a] indole-10-carboxamide for the preparation of a medicament for use as antagonist 5 -HT4 receptor in 2 treatment or prophylaxis of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
SI9300114A 1992-03-12 1993-03-10 5-ht4-receptor antagonists SI9300114B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929205428A GB9205428D0 (en) 1992-03-12 1992-03-12 Pharmaceuticals
GB929218846A GB9218846D0 (en) 1992-09-05 1992-09-05 Pharmaceuticals
GB929227045A GB9227045D0 (en) 1992-12-29 1992-12-29 Pharmaceuticals

Publications (2)

Publication Number Publication Date
SI9300114A SI9300114A (en) 1993-12-31
SI9300114B true SI9300114B (en) 2006-08-31

Family

ID=27266092

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300114A SI9300114B (en) 1992-03-12 1993-03-10 5-ht4-receptor antagonists

Country Status (30)

Country Link
EP (2) EP0884319B1 (en)
JP (1) JP2831467B2 (en)
KR (1) KR100282730B1 (en)
CN (2) CN1043893C (en)
AP (1) AP401A (en)
AT (2) ATE180785T1 (en)
AU (1) AU671102B2 (en)
CA (1) CA2131797C (en)
CY (1) CY2510B1 (en)
CZ (1) CZ286194B6 (en)
DE (2) DE69325167T2 (en)
DK (2) DK0884319T3 (en)
ES (2) ES2132223T3 (en)
FI (1) FI107158B (en)
GR (1) GR3030668T3 (en)
HK (1) HK1012352A1 (en)
HU (1) HU219121B (en)
IL (1) IL105003A (en)
MA (1) MA22819A1 (en)
MX (1) MX9301348A (en)
MY (1) MY110110A (en)
NO (1) NO303638B1 (en)
NZ (1) NZ249565A (en)
PT (1) PT884319E (en)
RU (1) RU2104279C1 (en)
SG (1) SG50693A1 (en)
SI (1) SI9300114B (en)
SK (1) SK281423B6 (en)
UA (1) UA41311C2 (en)
WO (1) WO1993018036A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9316195D0 (en) * 1993-08-05 1993-09-22 Smithkline Beecham Plc Pharmaceuticals
MX9305947A (en) * 1992-09-29 1994-06-30 Smithkline Beecham Plc ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
WO1994008965A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
EP0667867A1 (en) * 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
FR2699921B1 (en) * 1992-12-30 1995-02-10 Synthelabo 2- (Thien-2-yl) imidazo [2,1-b] benzothiazole-3-acetic acid derivatives, their preparation and their therapeutic use.
GB9303340D0 (en) * 1993-02-19 1993-04-07 Smithkline Beecham Plc Pharmaceuticals
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
GB9312348D0 (en) * 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
KR100219922B1 (en) * 1996-05-16 1999-09-01 이서봉 Novel antiviral 6-aryloxy and 6-arylcarbonyl 2,4-pyrimidinedione derivatives and process for the preparation thereof
KR980009260A (en) * 1996-07-02 1998-04-30 주상섭 Osiranic carboxylic acid derivative and its manufacturing method
NZ334064A (en) * 1996-08-16 2000-08-25 Smithkline Beecham Plc Process for the preparation of N-[(1-nbutyl-4-piperidyl)methyl] -3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process
US6100397A (en) * 1996-08-16 2000-08-08 Smithkline Beecham Plc Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process
GB9618967D0 (en) * 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals
GB9725933D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Pharmaceuticals
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
US20020091271A1 (en) 1998-07-16 2002-07-11 Smithkline Beecham Plc Process for the preparation of an indole derivative
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
EP1112270B1 (en) * 1998-09-10 2007-03-21 F. Hoffmann-La Roche Ag Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
GB9820294D0 (en) * 1998-09-17 1998-11-11 Smithkline Beecham Plc Pharmaceuticals
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2005203196B9 (en) * 2000-08-07 2009-04-09 Glaxo Group Limited The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU781276B2 (en) * 2000-08-07 2005-05-12 Glaxo Group Limited The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU782863C (en) * 2000-08-07 2006-08-31 Glaxo Group Limited The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU782870C (en) * 2000-08-07 2007-03-15 Glaxo Group Limited The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
CA2418921C (en) * 2000-08-08 2010-10-26 Smithkline Beecham P.L.C. Novel composition
DE60306120T2 (en) * 2002-02-14 2006-11-09 Glaxo Group Ltd., Greenford PHARMACEUTICAL FORMULATION, THE N - ((1-N-BUTYL-4-PIPERIDINYL) MENTHYL) -3,4-DIHYDRO-2H- (1,3) OXAZINO (3,2-A) INDOL-10-CARBOXAMIDE OR A CORRESPONDING SALT HEREBY CONTAINS, AS WELL AS THEIR MANUFACTURING PROCESS, WHICH CONTAINS DRY GRANULATION
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
ITMI20031468A1 (en) 2003-07-18 2005-01-19 Acraf ATIVE DRUG IN NEUROPATHIC PAIN
ITMI20031467A1 (en) * 2003-07-18 2005-01-19 Acraf ACTIVE DRUG IN NEUROPATHIC PAIN
DK1701951T3 (en) 2003-12-23 2010-06-07 Serodus As Modulators of peripheral 5-HT receptors
JP4612301B2 (en) * 2003-12-26 2011-01-12 広栄化学工業株式会社 Process for producing 1-alkyl-4-aminomethylpiperidine
MX2009013815A (en) 2007-06-22 2010-03-01 Arqule Inc Quinazolinone compounds and methods of use thereof.
GB0905641D0 (en) * 2009-04-01 2009-05-13 Serodus As Compounds
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (en) * 1975-12-19 1977-06-30 Hoechst Ag BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
CA2030051C (en) * 1989-11-17 2001-08-07 Haruhiko Kikuchi Indole derivatives
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
AP401A (en) 1995-08-29
FI944204A0 (en) 1994-09-12
CA2131797C (en) 2010-05-18
NO943348D0 (en) 1994-09-09
CN1043893C (en) 1999-06-30
EP0630376B1 (en) 1999-06-02
SK107894A3 (en) 1995-04-12
JPH07504433A (en) 1995-05-18
HUT71121A (en) 1995-11-28
SK281423B6 (en) 2001-03-12
DE69325167D1 (en) 1999-07-08
KR950700304A (en) 1995-01-16
EP0884319A3 (en) 1999-02-10
MY110110A (en) 1998-01-27
GR3030668T3 (en) 1999-10-29
AU3644893A (en) 1993-10-05
DE69333504T2 (en) 2005-05-12
JP2831467B2 (en) 1998-12-02
SI9300114A (en) 1993-12-31
FI944204A (en) 1994-09-12
NZ249565A (en) 1997-07-27
EP0630376A1 (en) 1994-12-28
MA22819A1 (en) 1993-10-01
AU671102B2 (en) 1996-08-15
ES2132223T3 (en) 1999-08-16
DK0884319T3 (en) 2004-08-30
SG50693A1 (en) 1998-07-20
WO1993018036A1 (en) 1993-09-16
EP0884319A2 (en) 1998-12-16
CN1085083A (en) 1994-04-13
CY2510B1 (en) 2005-12-23
AP9300494A0 (en) 1993-04-30
FI107158B (en) 2001-06-15
ES2219813T3 (en) 2004-12-01
RU94040864A (en) 1996-07-20
CZ221094A3 (en) 1995-09-13
ATE180785T1 (en) 1999-06-15
CN1078471A (en) 1993-11-17
NO943348L (en) 1994-11-09
IL105003A (en) 1996-09-12
UA41311C2 (en) 2001-09-17
MX9301348A (en) 1993-09-01
HU219121B (en) 2001-02-28
EP0884319B1 (en) 2004-05-06
ATE266033T1 (en) 2004-05-15
NO303638B1 (en) 1998-08-10
HK1012352A1 (en) 1999-07-30
DK0630376T3 (en) 1999-06-23
CZ286194B6 (en) 2000-02-16
RU2104279C1 (en) 1998-02-10
PT884319E (en) 2004-09-30
HU9402601D0 (en) 1994-12-28
CA2131797A1 (en) 1993-09-16
DE69333504D1 (en) 2004-06-09
KR100282730B1 (en) 2001-02-15
IL105003A0 (en) 1993-07-08
DE69325167T2 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
SI9300114B (en) 5-ht4-receptor antagonists
ES2125294T3 (en) IMIDAZO (1,2-A) PIRIDINES AS BRADIQUININE ANTAGONISTS.
MY130803A (en) New quinuclidine amide derivatives
MXPA04000278A (en) Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury.
HUP0203872A2 (en) Substituted 4-(phenyl-n-alkyl)-piperazine and piperidine-derivatives, their use as modulators of dopamine neurotransmission and pharmaceutical compositions containing them
ECSP941156A (en) 3 BENCILAMINOMETIL PIPERIDINES SUBSTITUTED WITH HETEROARILAMINO AND HETEROARILSULFONAMIDO AND RELATED COMPOUNDS
AR035235A1 (en) HETEROCICLILOXI DERIVATIVES -, - TIOXI- AND -AMINOBENZAZOL AS 5-HYDROXITRIPTAMINE-6 LINES, A PROCEDURE FOR PREPARATION, PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
ATE361917T1 (en) SELECTIVE NPY(Y5) ANTAGONISTS
TR200102136T2 (en) Substituted bicyclic derivatives useful as anticancer agents.
PT1029853E (en) U.S. HETEROAROMATIC BICYCLIC DERIVATIVES AS ANTICANCERIGENE AGENTS
SE9904508D0 (en) New compounds
PT734383E (en) DERIVATIVES OF CYCLIC AMIDES AS ANTAGONISTS OF NEUROCHININE A
UA85541C2 (en) Quinuclidine carbamate derivatives and pharmaceutical compositions containing the same
DE69131759D1 (en) Substituted 4H-pyrido- (1,2-a) pyrimidin-4-ones at positions 2 and 9
SE9901573D0 (en) New compounds
BR9909253A (en) 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists
EA199900161A1 (en) PYRIDAZINO [4,5-B] -QHINOLIN-5-OXIDE DERIVATIVES, THEIR RECEIVING AND APPLICATION AS ANTAGONISTS OF GLYCIN
DE69429591T2 (en) Therapeutically effective compounds
DE60001586D1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
MX9705801A (en) 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist.
ATE313539T1 (en) QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS
ES2138181T3 (en) BICYCLE HETEROCYCLES AS ANTAGONISTS OF NEUROKININ.
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
NO891390D0 (en) PROCEDURE FOR THE PREPARATION OF BICYCLIC AMINE COMPOUNDS.
SE9901572D0 (en) New compounds

Legal Events

Date Code Title Description
IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20060628